Revenue Performance - Revenues for Q3 2024 increased 14.3% to $770.4 million compared to $674.1 million in Q3 2023[2] - Year-to-date revenues for 2024 increased 12.1% to $2,249.9 million from $2,007.9 million in the prior year[3] - Total revenue for the three months ended September 30, 2024, was $770.4 million, a 14.3% increase from $674.1 million in the same period of 2023[16] - Same-facility revenues rose 4.2% year-over-year, with a 3.7% increase in same-facility cases[2] Adjusted EBITDA and Margins - Adjusted EBITDA for Q3 2024 was $128.6 million, reflecting a 21.9% growth from $105.5 million in Q3 2023[2] - The adjusted EBITDA margin expanded by 100 basis points to 16.7%[1] - Adjusted EBITDA for the three months ended September 30, 2024, was $128.6 million, up from $105.5 million in the prior year, representing a 21.8% increase[16] - The adjusted EBITDA margin for the three months ended September 30, 2024, was 16.7%, up from 15.7% in the prior year[14] Cash Flow and Debt - The company ended Q3 2024 with $222 million in cash and $596 million in revolver capacity[4] - Operating cash flows for Q3 2024 were $65.2 million, down from $104.6 million in the prior year quarter[4] - The total net debt to EBITDA ratio was approximately 3.8x at the end of Q3 2024[4] - Long-term debt, less current maturities, rose to $3,094.2 million as of September 30, 2024, compared to $2,701.8 million at the end of 2023, indicating a 14.6% increase[12] Surgical Facilities and Cases - The number of surgical facilities increased to 166 as of September 30, 2024, compared to 152 at the end of the previous year[14] - Cases performed in the three months ended September 30, 2024, totaled 162,635, a 11.1% increase from 146,514 in the same period of 2023[14] - Revenue per case for the three months ended September 30, 2024, was $4,737, compared to $4,601 in the prior year, reflecting a 2.9% increase[14] Net Income and Earnings - Adjusted net income per share attributable to common stockholders for the three months ended September 30, 2024, was $0.19, unchanged from the same period in 2023[14] - Adjusted net income attributable to common stockholders for Q3 2024 was $23.9 million, slightly up from $23.7 million in Q3 2023, indicating a 0.8% increase[24] - Net income for Q3 2024 was $6.4 million, a significant decrease from $29.7 million in Q3 2023, reflecting a decline of 78.5%[24] - Adjusted net income per share attributable to common stockholders remained stable at $0.19 for both Q3 2024 and Q3 2023[24] Costs and Expenses - Transaction, integration, and acquisition costs for Q3 2024 were $31.5 million, compared to $13.0 million in Q3 2023, marking a 142.3% increase[24] - Start-up costs related to unconsolidated de novo surgical facilities increased to $0.9 million in Q3 2024 from $0.5 million in Q3 2023, a rise of 80%[22] Management and Affiliates - Adjusted EBITDA related to unconsolidated affiliates for Q3 2024 was $12.9 million, up from $10.2 million in Q3 2023, representing a 26.5% increase[22] - Equity in earnings of unconsolidated affiliates rose to $5.2 million in Q3 2024 from $3.5 million in Q3 2023, a growth of 48.6%[22] - Management fee revenues increased to $6.8 million in Q3 2024 from $6.2 million in Q3 2023, a growth of 9.7%[22] Shareholder Information - Basic weighted average common shares outstanding increased to 126,172 in Q3 2024 from 125,747 in Q3 2023[24] - Diluted weighted average common shares outstanding rose to 127,640 in Q3 2024 from 127,376 in Q3 2023[24]

Wall Street expects a year-over-year increase in earnings on higher revenues when Surgery Partners (SGRY) reports results for the quarter ended September 2024. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on November 12, 2024, might help the stock move higher if these key numbers are bette ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________________ Form 10-Q _____________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-37576 Surgery Partners, Inc. (Exact name of registrant as specified in its charter) De ...

Surgery Partners, Inc. (NASDAQ:SGRY) Q2 2024 Earnings Conference Call August 6, 2024 8:30 AM ET Company Participants Dave Doherty – Chief Financial Officer Wayne DeVeydt – Executive Chairman Eric Evans – Chief Executive Officer Conference Call Participants Brian Tanquilut – Jefferies Tao Qiu – Macquarie Kevin Fischbeck – Bank of America Andrew Mok – Barclays Jason Cassorla – Citi Bill Sutherland – Benchmark Company Whit Mayo – Leerink Partners Will Spivack – TD Cowen Operator Good day, everyone, and welcome ...

Surgery Partners (SGRY) came out with quarterly earnings of $0.21 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.28 per share a year ago. These figures are adjusted for non-recurring items. A quarter ago, it was expected that this surgical facilities operator would post earnings of $0.07 per share when it actually produced earnings of $0.10, delivering a surprise of 42.86%. Over the last four quarters, the company has surpassed consensus EPS estimates three times. Surg ...

Exhibit 99.1 1 SURGERY PARTNERS, INC. ANNOUNCES SECOND QUARTER 2024 RESULTS RAISES FULL YEAR 2024 GUIDANCE BRENTWOOD, Tenn., August 6, 2024 (GLOBE NEWSWIRE) - Surgery Partners, Inc. (NASDAQ:SGRY) ("Surgery Partners" or the "Company"), a leading short-stay surgical facility owner and operator, today announced results for the second quarter ended June 30, 2024. • Revenues increased 14.2% to $762.1 million compared to the prior year period ◦ Same-facility revenues increased 9.9% ◦ Same-facility cases increased ...

BRENTWOOD, Tenn., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) ("Surgery Partners" or the "Company"), a leading short-stay surgical facility owner and operator, today announced results for the second quarter ended June 30, 2024. Revenues increased 14.2% to $762.1 million compared to the prior year period Same-facility revenues increased 9.9% Same-facility cases increased 3.9% Net loss attributable to Surgery Partners, Inc. was $15.5 million Adjusted EBITDA was $118.3 million, repre ...

Investors looking for stocks in the Medical Services sector might want to consider either Surgery Partners (SGRY) or Medpace (MEDP) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look. There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The Zacks Rank favors stocks with stro ...

Investors interested in stocks from the Medical Services sector have probably already heard of Surgery Partners (SGRY) and Medpace (MEDP) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look. Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The proven Zacks Rank puts an emphasis on earnings estim ...

Surgery Partners (SGRY) closed the last trading session at $25.55, gaining 0.9% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $40.25 indicates a 57.5% upside potential. While the consensus price target is highly sought after by investors, the ability and unbiasedness of analysts in setting price targets have long been questionable. And investors making investment decisions solely ...